CG Oncology Inc. (CGON)
NASDAQ: CGON · Biological Products, (No Diagnostic Substances) · Dallas, TX
Our rating: Cautious
Cautious reaffirmed at $74.74, moderate conviction, November 9, 2026.
Breaks if: The cautious call is wrong if CG Oncology's filings show product revenue exceeding $75 million on an annualized run rate within the next two quarterly reports, demonstrating that a commercial launch is gaining traction quickly enough to begin justifying the $6.7 billion market cap. On the upside, a sustained move above $100 within six months — anchored to disclosed revenue progress rather than momentum — would signal the market has credible evidence the thesis is playing out ahead of this timeline. Conversely, the call is reinforced rather than invalidated if free cash flow deteriorates beyond negative $170 million annualized without a corresponding revenue line appearing in the filings.
Key figures
| Market value | $7.1B |
|---|---|
| Revenue, last 12 months | $6M |
| Net income, last 12 months | −$237M |
| Free cash flow, last 12 months | −$189M |
| Price to earnings | n/a |
| Free cash flow yield | −2.7% |
| Dividend yield | 0.0% |
| Operating margin | −4293.5% |
| Return on equity | −28.3% |
| Beta to the S&P 500 | 1.31 |
| Volatility, annualized | 60.9% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $2M | −3.7% | $-0.64 | −$49M |
| June 30, 2026 | $1M | n/a | $-0.90 | −$47M |
| March 31, 2026 | $1M | 1982.7% | $-0.71 | −$57M |
| December 31, 2025 | $2M | 409.2% | $-0.51 | −$36M |
| September 30, 2025 | $2M | 3774.4% | $-0.57 | −$39M |
| June 30, 2025 | $0.00 | −100.0% | $-0.54 | −$28M |
| March 31, 2025 | $52000.00 | −90.2% | $-0.45 | −$29M |
| December 31, 2024 | $456000.00 | 45500.0% | $-0.48 | −$21M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.02B: Claude 4%, Gemini 5%, Mistral 2%
- Diluted earnings per share are above zero: Claude 3%, Gemini 1%, Mistral 1%
- Free cash flow for the quarter is above zero: Claude 4%, Gemini 1%, Mistral 2%
20 ledger entries and 7 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.